Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron Pharmaceuticals serves the healthcare sector in the United States.
Website: regeneron.com



Growth: Bad revenue growth rate -16.4%, there is slowdown compared to average historical growth rates -6.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +26.7%

Profitability: LTM EBITDA margin is positive, +62.8%. On average the margin is improving unsteadily. Gross margin is high, +86.3%. In the last quarter the company beat the estimated EPS, +5.5%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$1.48 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.5%. Free cash flow yield 1.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 57.9% higher than minimum and 36.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.1x by EV / Sales multiple , the company can be 60.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $2.1 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: REGN
Share price, USD:  (0.0%)762.65
year average price 629.21  


year start price 710.00 2025-02-07

min close price 483.07 2025-06-05

max close price 787.32 2025-11-25

current price 762.65 2026-02-07
Common stocks: 107 100 000

Dividend Yield:  0.5%
FCF Yield LTM: 1.2%
EV / LTM EBITDA: 16.5x
EV / EBITDA annualized: 17.2x
Last revenue growth (y/y):  -16.4%
Last growth of EBITDA (y/y):  -10.3%
Historical revenue growth:  -6.1%
Historical growth of EBITDA:  -7.4%
EV / Sales: 10.4x
Margin (EBITDA LTM / Revenue): 62.8%
Fundamental value created in LTM:
Market Cap ($m): 81 680
Net Debt ($m): -16 160
EV (Enterprise Value): 65 520
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-31seekingalpha.com

Regeneron: Expect Double-Digit Growth In 2026

2026-01-30seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

2026-01-30reuters.com

Regeneron bets added cholesterol benefit will help its obesity drug stand out

2026-01-30zacks.com

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

2026-01-30reuters.com

Regeneron beats quarterly profit estimates on Dupixent strength

2026-01-30globenewswire.com

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

2026-01-30benzinga.com

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

2026-01-28zacks.com

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?

2026-01-23seekingalpha.com

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

2026-01-23zacks.com

REGN or ILMN: Which Is the Better Value Stock Right Now?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589
filingDate 2026-02-04 2025-02-05 2024-02-05 2023-02-06 2022-02-07 2021-02-08
acceptedDate 2026-02-04 09:08:38 2025-10-28 06:56:36 2025-08-01 06:56:11 2025-02-05 09:18:14 2024-10-31 07:16:48 2024-08-01 07:15:21 2024-05-02 07:13:11 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44 2022-02-07 09:25:49 2021-02-08 09:13:00
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 14 343M 3 754M 3 676M 14 202M 3 721M 3 547M 3 145M 13 117M 3 363M 3 158M 3 162M 12 173M 2 936M 16 072M 8 497M
costOfRevenue 1 969M 522M 530M 1 971M 491M 601M 548M 2 245M 212M 405M 458M 1 705M 318M 2 724M 1 356M
grossProfit 12 374M 3 233M 3 145M 12 232M 3 230M 2 946M 2 597M 10 873M 3 151M 2 753M 2 705M 10 468M 2 618M 13 348M 7 141M
researchAndDevelopmentExpenses 5 850M 1 558M 1 432M 5 233M 1 272M 1 079M 1 134M 3 987M 1 075M 1 085M 1 101M 3 056M 911M 2 622M 2 499M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2 700M 658M 634M 2 954M 714M 759M 689M 2 540M 641M 652M 601M 2 116M 529M 1 825M 1 346M
otherExpenses 131M -10M 0 53M 64M -15M -15M -2M -16M 85M -500 000 -90M -46M -46M -280M
operatingExpenses 8 681M 2 206M 2 066M 8 241M 2 050M 1 853M 1 839M 6 524M 1 716M 1 737M 1 702M 5 082M 1 395M 4 401M 3 565M
costAndExpenses 10 650M 2 728M 2 596M 10 211M 2 541M 2 454M 2 387M 8 769M 1 928M 2 142M 2 159M 6 787M 1 713M 7 125M 4 921M
netInterestIncome -44M 656M 423M 101M -57M -57M
interestIncome 0 175M 175M 711M 187M 179M 162M 496M 134M 0 0 160M 0 0 0
interestExpense 44M 19M 4M 55M 14M 15M 16M 73M -18M 19M 18M 59M 15M 57M 57M
depreciationAndAmortization 532M 137M 135M 483M 122M 121M 114M 421M 105M 103M 85M 341M 394M 286M 236M
ebitda 5 806M 1 919M 1 657M 5 318M 1 629M 1 214M 873M 4 693M 1 111M 1 205M 1 032M 5 260M 1 618M 9 669M 4 103M
ebit 5 275M 4 835M 4 272M 4 918M 9 383M 3 867M
nonOperatingIncomeExcludingInterest -1 582M -844M 76M 467M -436M -291M
operatingIncome 3 693M 1 027M 1 080M 3 991M 1 180M 1 094M 759M 4 349M 1 111M 1 017M 947M 5 386M 1 224M 8 947M 3 577M
totalOtherIncomeExpensesNet 1 538M 737M 439M 789M 314M 559M -58M -149M -200 000 85M -89M -527M 286M 379M 234M
incomeBeforeTax 5 231M 1 763M 1 519M 4 780M 1 493M 1 628M 701M 4 199M 1 111M 1 083M 858M 4 859M 1 510M 9 326M 3 810M
incomeTaxExpense 726M 303M 127M 367M 152M 196M -21M 246M 103M 115M 40M 520M 194M 1 251M 297M
netIncomeFromContinuingOperations 4 505M 4 413M 3 954M 4 338M 8 075M 3 513M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0 0
netIncome 4 505M 1 460M 1 392M 4 413M 1 341M 1 432M 722M 3 954M 1 008M 968M 818M 4 338M 1 316M 8 075M 3 513M
netIncomeDeductions 0 0 0 0 0 0
bottomLineNetIncome 4 505M 4 413M 3 954M 4 338M 8 075M 3 513M
eps 43.07 14.09 13.24 40.9 12.4 13.25 6.7 37.05 9.48 9.05 7.64 40.51 12.31 76.4 32.65
epsDiluted 41.48 38.34 34.77 38.22 71.97 30.52
weightedAverageShsOut 105M 104M 105M 108M 108M 108M 108M 107M 106M 114M 107M 107M 107M 106M 108M
weightedAverageShsOutDil 109M 107M 109M 115M 116M 115M 115M 114M 113M 114M 114M 114M 113M 112M 115M
fillingDate 2025-10-28 2025-08-01 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.861 0.856 0.868 0.831 0.826 0.937 0.872 0.855 0.892
ebitdaratio 0.511 0.451 0.438 0.342 0.277 0.33 0.382 0.326 0.551
operatingIncomeRatio 0.273 0.294 0.317 0.308 0.241 0.33 0.322 0.299 0.417
incomeBeforeTaxRatio 0.47 0.413 0.401 0.459 0.223 0.33 0.343 0.271 0.514
netIncomeRatio 0.389 0.379 0.36 0.404 0.23 0.3 0.307 0.259 0.448
epsdiluted 13.62 12.81 11.54 12.41 6.27 8.89 8.5 7.17 11.66
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589
filingDate 2026-02-04 2025-02-05 2024-02-05 2023-02-06 2022-02-07 2021-02-08
acceptedDate 2026-02-04 09:08:38 2025-10-28 06:56:36 2025-08-01 06:56:11 2025-02-05 09:18:14 2024-10-31 07:16:48 2024-08-01 07:15:21 2024-05-02 07:13:11 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44 2022-02-07 09:25:49 2021-02-08 09:13:00
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 18 866M 2 506M 1 996M 2 488M 2 012M 1 928M 2 602M 2 730M 2 152M 1 937M 3 916M 3 106M 3 491M 2 886M 2 194M
shortTermInvestments 0 5 937M 5 474M 6 524M 7 785M 7 888M 7 918M 8 115M 7 761M 6 991M 5 043M 4 636M 3 530M 2 809M 1 393M
cashAndShortTermInvestments 18 866M 8 444M 7 470M 9 013M 9 797M 9 817M 10 520M 10 845M 9 914M 8 928M 8 960M 7 742M 7 022M 5 695M 3 587M
netReceivables 5 741M 5 687M 5 610M 6 212M 6 107M 5 717M 5 222M 5 667M 5 585M 5 121M 5 119M 5 329M 5 548M 6 037M 4 115M
accountsReceivables 5 741M 6 212M 5 667M 5 329M 6 037M 4 115M
otherReceivables 0 0 0 0 0 0
inventory 3 201M 3 254M 3 206M 3 087M 3 018M 2 874M 2 715M 2 581M 2 562M 2 008M 1 870M 2 402M 2 412M 1 951M 1 917M
prepaids 0 0 0 411M 332M 161M
otherCurrentAssets 0 596M 574M 349M 412M 682M 415M 387M 575M 361M 406M 0 446M 0 0
totalCurrentAssets 27 808M 17 981M 16 860M 18 661M 19 334M 19 082M 18 872M 19 479M 18 635M 16 923M 16 909M 15 884M 15 429M 14 015M 9 779M
propertyPlantEquipmentNet 5 120M 5 002M 4 841M 4 600M 4 439M 4 306M 4 226M 4 146M 4 006M 3 923M 3 881M 3 763M 3 704M 3 482M 3 222M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 1 257M 1 381M 1 352M 1 149M 1 120M 1 102M 1 059M 1 039M 1 017M 953M 929M 916M 804M 7M 0
goodwillAndIntangibleAssets 1 257M 1 381M 1 352M 1 149M 1 120M 1 102M 1 059M 1 039M 1 017M 953M 929M 916M 804M 7M 0
longTermInvestments 0 10 286M 10 058M 8 900M 8 491M 7 919M 7 060M 5 397M 5 779M 6 327M 6 067M 6 592M 5 969M 6 838M 3 136M
taxAssets 4 077M 3 847M 3 572M 3 314M 3 015M 2 881M 2 765M 2 575M 2 317M 2 139M 1 925M 1 724M 1 452M 877M 859M
otherNonCurrentAssets 2 296M 1 673M 1 537M 1 136M 1 043M 797M 389M 444M 410M 393M 350M 336M 320M 216M 168M
totalNonCurrentAssets 12 751M 22 189M 21 360M 19 099M 18 108M 17 005M 15 498M 13 601M 13 529M 13 735M 13 151M 13 330M 12 249M 11 420M 7 384M
otherAssets 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 40 559M 40 169M 38 219M 37 759M 37 442M 36 087M 34 370M 33 080M 32 163M 30 658M 30 060M 29 215M 27 678M 25 435M 17 163M
totalPayables 5 834M 1 003M 618M 589M 1 178M 511M
accountPayables 5 834M 904M 724M 790M 497M 562M 671M 607M 537M 547M 600M 589M 536M 564M 476M
otherPayables 0 213M 12M 0 614M 36M
accruedExpenses 0 2 314M 2 346M 2 074M 1 593M 1 609M
shortTermDebt 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 720M 0
taxPayables 0 0 0 213M 0 0 0 0 0 0 0 300 000 0 326M 20M
deferredRevenue 553M 546M 482M 628M 627M 586M 517M 459M 417M 381M 426M 478M 547M 442M 578M
otherCurrentLiabilities -553M 2 976M 2 461M 0 2 537M 2 361M 2 393M 0 2 645M 2 176M 2 074M 0 1 796M 0 0
totalCurrentLiabilities 5 834M 4 425M 3 667M 3 944M 3 661M 3 509M 3 581M 3 423M 3 599M 3 104M 3 100M 3 141M 2 879M 3 933M 2 697M
longTermDebt 1 986M 2 706M 2 705M 1 984M 2 704M 2 704M 1 983M 1 983M 2 703M 2 702M 2 702M 1 981M 2 701M 1 980M 1 979M
capitalLeaseObligationsNonCurrent 720M 720M 720M 720M 0 717M
deferredRevenueNonCurrent 762M 219M 206M 186M 0 206M 186M 127M 125M 116M 86M 70M 60M 73M 58M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 720M 720M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 1 862M 1 702M 1 571M 1 751M 1 463M 909M 854M 832M 717M 677M 638M 2 277M 680M 687M
totalNonCurrentLiabilities 3 468M 4 787M 4 613M 4 462M 4 455M 4 372M 3 798M 3 684M 3 660M 3 535M 3 465M 3 409M 3 360M 2 734M 3 441M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 720M 720M 720M 720M 720M 720M 720M 720M 720M 720M 720M 720M 720M 720M 717M
totalLiabilities 9 302M 9 212M 8 280M 8 406M 8 116M 7 881M 7 379M 7 107M 7 259M 6 640M 6 565M 6 551M 6 239M 6 666M 6 138M
treasuryStock -17 944M -15 167M -12 560M -10 353M -8 261M -6 613M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings 35 797M 35 046M 33 680M 31 673M 30 755M 29 415M 27 982M 27 260M 26 101M 25 093M 24 125M 23 307M 22 110M 18 968M 10 893M
additionalPaidInCapital 13 327M 12 856M 11 354M 9 949M 8 088M 6 716M
accumulatedOtherComprehensiveIncomeLoss 78M 69M 53M -8M 60M -70M -77M -81M -177M -198M -182M -239M -275M -26M 29M
otherTotalStockholdersEquity 0 0 0 0 0 0
totalStockholdersEquity 31 257M 30 958M 29 939M 29 354M 29 326M 28 206M 26 991M 25 973M 24 904M 24 018M 23 495M 22 664M 21 439M 18 769M 11 025M
totalEquity 31 257M 30 958M 29 939M 29 354M 29 326M 28 206M 26 991M 25 973M 24 904M 24 018M 23 495M 22 664M 21 439M 18 769M 11 025M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 40 559M 40 169M 38 219M 37 759M 37 442M 36 087M 34 370M 33 080M 32 163M 30 658M 30 060M 29 215M 27 678M 25 435M 17 163M
totalInvestments 0 16 223M 15 532M 15 424M 16 276M 15 808M 14 978M 13 511M 7 761M 6 991M 5 043M 11 228M 9 499M 9 647M 4 529M
totalDebt 2 706M 2 706M 2 705M 2 704M 2 704M 2 704M 2 703M 2 703M 2 703M 2 702M 2 702M 2 701M 2 701M 2 700M 2 696M
netDebt -16 160M 199M 709M 216M 692M 775M 101M -27M 550M 765M -1 215M -405M -790M -186M 502M
fillingDate 2025-10-28 2025-08-01 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
othertotalStockholdersEquity -4 157M -3 794M -1 490M -1 139M -914M -1 020M -877M -448M -396M
totalLiabilitiesAndStockholdersEquity 40 169M 38 219M 37 442M 36 087M 34 370M 32 163M 30 658M 30 060M 27 678M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589 872 589
filingDate 2026-02-04 2025-02-05 2024-02-05 2023-02-06 2022-02-07 2021-02-08
acceptedDate 2026-02-04 09:08:38 2025-10-28 06:56:36 2025-08-01 06:56:11 2025-02-05 09:18:14 2024-10-31 07:16:48 2024-08-01 07:15:21 2024-05-02 07:13:11 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44 2022-02-07 09:25:49 2021-02-08 09:13:00
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 4 505M 1 460M 1 392M 4 413M 1 341M 1 432M 722M 3 954M 1 008M 968M 818M 4 338M 1 316M 8 075M 3 513M
depreciationAndAmortization 544M 137M 135M 483M 122M 121M 114M 421M 105M 103M 100M 341M 93M 286M 236M
deferredIncomeTax -785M -279M -135M -757M -169M -118M -190M -838M -126M -209M -217M -746M -86M -147M 76M
stockBasedCompensation 994M 237M 252M 983M 225M 223M 230M 885M 204M 202M 239M 725M 166M 602M 432M
changeInWorkingCapital 0 98M -228M -618M 468M -909M 441M -94M -192M -81M 241M -243M -667M -1 917M -1 504M
accountsReceivables 498M -80M -28M -554M -389M -494M 447M -339M -464M -3M 210M 708M -387M -1 927M -1 356M
inventory -275M -83M -43M -620M -164M -182M -156M -272M -77M -100M -47M -697M -224M -494M -529M
accountsPayables 737M 759M 216M 735M 194M 205M 111M 599M 303M 40M 119M -138M -160M 866M 119M
otherWorkingCapital 0 -498M -374M -180M 827M -437M 39M -82M 45M -18M -41M -116M 104M -361M 263M
otherNonCashItems -278M -35M -271M -82M -696M 540M 253M 266M 115M 40M 187M 600M -193M 182M -135M
netCashProvidedByOperatingActivities 4 979M 1 619M 1 144M 4 421M 1 291M 354M 1 513M 4 594M 1 114M 1 022M 1 368M 5 015M 629M 7 081M 2 618M
investmentsInPropertyPlantAndEquipment -898M -201M -219M -756M -184M -211M -162M -926M -176M -113M -279M -590M -1 069M -552M -615M
acquisitionsNet -3M -3M 0 -17M 0 15M 0 -55M 200M 134M 101M -230M 0 552M 615M
purchasesOfInvestments -10 958M -3 520M -2 855M -16 617M -4 591M -4 416M -5 658M -11 646M -3 243M -4 522M -1 749M -7 488M -570M -7 048M -3 241M
salesMaturitiesOfInvestments 11 546M 3 365M 2 168M 15 027M 4 259M 4 055M 4 132M 9 442M 2 998M 2 269M 1 793M 5 551M 1 832M 2 215M 3 785M
otherInvestingActivities -315M -106M 0 -1 027M -552M -615M
netCashProvidedByInvestingActivities -629M -2 468M -3 185M -3 785M -5 385M -71M
netDebtIssuance 0 0 0 0 0 1 982M
longTermNetDebtIssuance 0 0 0 0 0 1 982M
shortTermNetDebtIssuance 0 0 0 0 0 0
netStockIssuance 0 -2 167M -1 790M -563M 27M -6 528M
netCommonStockIssuance 0 -2 167M -1 790M -1 009M -1 006M -3 952M
commonStockIssuance 636M 1 465M 1 146M 1 520M 1 672M 2 575M
commonStockRepurchased -3 439M -660M -1 062M -3 632M -735M -916M -291M -2 936M -676M -705M -808M -2 529M -1 044M -2 678M -6 528M
netPreferredStockIssuance 0 0 0 446M 1 033M -2 575M
netDividendsPaid -370M 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0 0
otherFinancingActivities -3 345M -33M 0 -446M -1 033M 2 575M
netCashProvidedByFinancingActivities -3 715M -2 201M -1 790M -1 009M -1 006M -1 971M
effectOfForexChangesOnCash 300 000 -400 000 400 000 -700 000 800 000 -300 000 -500 000 -400 000 -200 000 3 765M 0 0 0 0 0
netChangeInCash 635M 498M -1 077M -249M 84M -674M -128M -382M 211M -1 979M 809M 221M 96M 691M 577M
cashAtEndOfPeriod 3 124M 2 513M 2 016M 2 489M 2 012M 1 928M 2 602M 2 738M 2 160M 1 950M 3 929M 3 119M 3 505M 2 898M 2 207M
cashAtBeginningOfPeriod 2 489M 2 016M 3 093M 2 738M 1 928M 2 602M 2 730M 3 119M 1 950M 3 929M 3 119M 2 898M 3 409M 2 207M 1 630M
operatingCashFlow 4 979M 1 619M 1 144M 4 421M 1 291M 354M 1 513M 4 594M 1 114M 1 022M 1 368M 5 015M 629M 7 081M 2 618M
capitalExpenditure -898M -201M -177M -756M -184M -211M -162M -926M -176M -113M -279M -590M -1 069M -552M -615M
freeCashFlow 4 081M 1 417M 968M 3 665M 1 108M 143M 1 351M 3 668M 938M 909M 1 089M 4 425M -440M 6 529M 2 004M
incomeTaxesPaid 0 743M 870M 1 502M 1 218M 188M
interestPaid 0 53M 73M 54M 56M 23M
fillingDate 2025-10-28 2025-08-01 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
otherInvestingActivites -43M -188M -58M -372M -1 553M -275M -155M -101M 0
netCashUsedForInvestingActivites -403M -1 094M -574M -557M -1 687M -496M -2 387M -236M 192M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 40M 32M 255M 438M 682M 269M 91M 485M 319M
dividendsPaid -91M -93M 0 0 0 0 0 0 0
otherFinancingActivites -7M -6M -154M 0 -344M -129M 0 0 0
netCashUsedProvidedByFinancingActivities -718M -1 128M -634M -478M 47M -407M -614M -323M -725M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q4
2026-01-30 ET (fiscal 2025 q4)
2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-08-01 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-04 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-02 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-03 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-30 06:51 ET
Regeneron Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-30 06:51 ET
Regeneron Pharmaceuticals reported for 2025 q4
SEC form 10
2025-10-28 10:56 ET
Regeneron Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-28 10:50 ET
Regeneron Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-28 10:50 ET
Regeneron Pharmaceuticals reported for 2025 q3
SEC form 10
2025-08-01 06:56 ET
Regeneron Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-01 06:49 ET
Regeneron Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-01 06:49 ET
Regeneron Pharmaceuticals reported for 2025 q2
SEC form 10
2025-04-29 10:51 ET
Regeneron Pharmaceuticals published news for 2025 q1
SEC form 10
2025-04-29 00:00 ET
Regeneron Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Regeneron Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Regeneron Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-05 14:18 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-05 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-04 07:11 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-04 07:11 ET
Regeneron Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 07:16 ET
Regeneron Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 07:10 ET
Regeneron Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-31 07:10 ET
Regeneron Pharmaceuticals reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Regeneron Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-07 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:15 ET
Regeneron Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-01 07:06 ET
Regeneron Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 07:06 ET
Regeneron Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-08 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-02 07:13 ET
Regeneron Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-02 07:06 ET
Regeneron Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-02 07:06 ET
Regeneron Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Regeneron Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-05 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Regeneron Pharmaceuticals reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 07:22 ET
Regeneron Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-02 07:10 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-05 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 06:56 ET
Regeneron Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 06:48 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-14 16:07 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-10 07:01 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 8
2023-04-10 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-29 16:01 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-06 09:23 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-06 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-03 07:06 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:49 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-20 16:01 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 07:25 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 07:19 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-05 16:04 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 07:17 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-03 07:21 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 07:08 ET
Regeneron Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-15 16:11 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-02 07:36 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 07:17 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 07:08 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-21 16:09 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-08 06:15 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-07 09:25 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-07 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-04 07:29 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 06:02 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 07:19 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 07:12 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-16 16:01 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 07:11 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-05 06:59 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-16 16:36 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 07:21 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 07:12 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:11 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-08 09:13 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-05 07:34 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-15 16:01 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 06:03 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-05 06:03 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 10
2020-11-05 07:48 ET
Regeneron Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 07:32 ET
Regeneron Pharmaceuticals published news for 2020 q3